Kineta to Present at Upcoming Investor Conferences

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:

BIO CEO and Investor ConferenceDate:   Monday, February 26, 2024Time:   9:45 A.M.– 10:00 A.M. Eastern TimeFormat: Presentation and 1:1 meetingsLocation: The New York Marriott Marquis, Uris room

10th Annual Immuno-Oncology 360 Conference (IO360) Date: February 27-29, 2024Format: 1:1 meetingsLocation: New York Marriott at the Brooklyn Bridge

Opal Group Family Office Winter ForumDate:   Monday, March 4, 2024Time:   12:30 P.M.– 12:50 P.M. Eastern TimeFormat: Presentation and 1:1 meetingsLocation: etc.venues 360 Madison, New York, NY

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

About KinetaKineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on X (Twitter), LinkedIn and Facebook.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kineta, Inc.:Jacques BouchyEVP Investor Relations & Business Development+1 206-378-0400[email protected]

Investor Relations:Bruce MackleLifeSci Advisors, LLC[email protected]

Source: Kineta, Inc.

Source: Kineta, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cerrado Gold Announces Second Quarter 2026 Financial Results
• Immunocine Cancer Center Expands as Demand Grows for Personalized Dendritic Cell Therapy
• IC Group Holdings Inc. Announces Change of Auditor